CytoSorbents Reports Initial Data Analysis from the STAR-T Study of DrugSorb-ATR to Reduce Perioperative Bleeding
Shots:
- The US and Canadian STAR-T study evaluates DrugSorb-ATR's efficacy in minimizing perioperative bleeding in patients (n=140) randomized to 1:1 on ticagrelor undergoing cardiothoracic surgery without completing the recommended washout period
- The trial showed a reduction in bleeding complications in patients undergoing isolated coronary artery bypass graft (CABG) surgery (90%) and did not meet the 1EP of effectiveness for the overall patient population undergoing various cardiac surgeries. The independent DSMB also confirmed the device's safety
- The company anticipates full trial analysis data in the coming weeks which may support the regulatory submission of DrugSorb-ATR to the US FDA and HC
Ref: CytoSorbents | Image: Cytosorbents
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
